Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Identifieur interne : 000062 ( Main/Exploration ); précédent : 000061; suivant : 000063Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
Auteurs : Amjad Husain [Inde] ; Siddappa N. Byrareddy [États-Unis]Source :
- Chemico-biological interactions [ 1872-7786 ] ; 2020.
Descripteurs français
- KwdFr :
- Betacoronavirus (isolement et purification), Betacoronavirus (physiologie), Cytokines (métabolisme), Expression des gènes (effets des médicaments et des substances chimiques), Humains (MeSH), Infections à coronavirus (anatomopathologie), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Pandémies (MeSH), Pneumopathie virale (anatomopathologie), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Prolifération cellulaire (effets des médicaments et des substances chimiques), Repositionnement des médicaments (MeSH), Réplication virale (effets des médicaments et des substances chimiques), Sirolimus (pharmacologie), Sirolimus (usage thérapeutique), Sérine-thréonine kinases TOR (antagonistes et inhibiteurs), Sérine-thréonine kinases TOR (métabolisme).
- MESH :
- anatomopathologie : Infections à coronavirus, Pneumopathie virale.
- antagonistes et inhibiteurs : Sérine-thréonine kinases TOR.
- effets des médicaments et des substances chimiques : Expression des gènes, Prolifération cellulaire, Réplication virale.
- isolement et purification : Betacoronavirus.
- métabolisme : Cytokines, Sérine-thréonine kinases TOR.
- pharmacologie : Sirolimus.
- physiologie : Betacoronavirus.
- traitement médicamenteux : Infections à coronavirus, Pneumopathie virale.
- usage thérapeutique : Sirolimus.
- virologie : Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies, Repositionnement des médicaments.
English descriptors
- KwdEn :
- Betacoronavirus (isolation & purification), Betacoronavirus (physiology), Cell Proliferation (drug effects), Coronavirus Infections (drug therapy), Coronavirus Infections (pathology), Coronavirus Infections (virology), Cytokines (metabolism), Drug Repositioning (MeSH), Gene Expression (drug effects), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (pathology), Pneumonia, Viral (virology), Sirolimus (pharmacology), Sirolimus (therapeutic use), TOR Serine-Threonine Kinases (antagonists & inhibitors), TOR Serine-Threonine Kinases (metabolism), Virus Replication (drug effects).
- MESH :
- chemical , antagonists & inhibitors : TOR Serine-Threonine Kinases.
- chemical , metabolism : Cytokines, TOR Serine-Threonine Kinases.
- drug effects : Cell Proliferation, Gene Expression, Virus Replication.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- isolation & purification : Betacoronavirus.
- pathology : Coronavirus Infections, Pneumonia, Viral.
- chemical , pharmacology : Sirolimus.
- physiology : Betacoronavirus.
- chemical , therapeutic use : Sirolimus.
- virology : Coronavirus Infections, Pneumonia, Viral.
- Drug Repositioning, Humans, Pandemics.
Abstract
The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection.
DOI: 10.1016/j.cbi.2020.109282
PubMed: 33031791
PubMed Central: PMC7536130
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.</title><author><name sortKey="Husain, Amjad" sort="Husain, Amjad" uniqKey="Husain A" first="Amjad" last="Husain">Amjad Husain</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India; Innovation and Incubation Centre for Entrepreneurship, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India. Electronic address: amjad@iiserb.ac.in.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India; Innovation and Incubation Centre for Entrepreneurship, Indian Institute of Science Education and Research (IISER), Bhopal, MP</wicri:regionArea><wicri:noRegion>MP</wicri:noRegion></affiliation></author><author><name sortKey="Byrareddy, Siddappa N" sort="Byrareddy, Siddappa N" uniqKey="Byrareddy S" first="Siddappa N" last="Byrareddy">Siddappa N. Byrareddy</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, NE</wicri:regionArea><placeName><region type="state">Nebraska</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:33031791</idno><idno type="pmid">33031791</idno><idno type="doi">10.1016/j.cbi.2020.109282</idno><idno type="pmc">PMC7536130</idno><idno type="wicri:Area/Main/Corpus">000015</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000015</idno><idno type="wicri:Area/Main/Curation">000015</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000015</idno><idno type="wicri:Area/Main/Exploration">000015</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.</title><author><name sortKey="Husain, Amjad" sort="Husain, Amjad" uniqKey="Husain A" first="Amjad" last="Husain">Amjad Husain</name><affiliation wicri:level="1"><nlm:affiliation>Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India; Innovation and Incubation Centre for Entrepreneurship, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India. Electronic address: amjad@iiserb.ac.in.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India; Innovation and Incubation Centre for Entrepreneurship, Indian Institute of Science Education and Research (IISER), Bhopal, MP</wicri:regionArea><wicri:noRegion>MP</wicri:noRegion></affiliation></author><author><name sortKey="Byrareddy, Siddappa N" sort="Byrareddy, Siddappa N" uniqKey="Byrareddy S" first="Siddappa N" last="Byrareddy">Siddappa N. Byrareddy</name><affiliation wicri:level="2"><nlm:affiliation>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, NE</wicri:regionArea><placeName><region type="state">Nebraska</region></placeName></affiliation></author></analytic><series><title level="j">Chemico-biological interactions</title><idno type="eISSN">1872-7786</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Betacoronavirus (isolation & purification)</term><term>Betacoronavirus (physiology)</term><term>Cell Proliferation (drug effects)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (pathology)</term><term>Coronavirus Infections (virology)</term><term>Cytokines (metabolism)</term><term>Drug Repositioning (MeSH)</term><term>Gene Expression (drug effects)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (drug therapy)</term><term>Pneumonia, Viral (pathology)</term><term>Pneumonia, Viral (virology)</term><term>Sirolimus (pharmacology)</term><term>Sirolimus (therapeutic use)</term><term>TOR Serine-Threonine Kinases (antagonists & inhibitors)</term><term>TOR Serine-Threonine Kinases (metabolism)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Betacoronavirus (isolement et purification)</term><term>Betacoronavirus (physiologie)</term><term>Cytokines (métabolisme)</term><term>Expression des gènes (effets des médicaments et des substances chimiques)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (anatomopathologie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Infections à coronavirus (virologie)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (anatomopathologie)</term><term>Pneumopathie virale (traitement médicamenteux)</term><term>Pneumopathie virale (virologie)</term><term>Prolifération cellulaire (effets des médicaments et des substances chimiques)</term><term>Repositionnement des médicaments (MeSH)</term><term>Réplication virale (effets des médicaments et des substances chimiques)</term><term>Sirolimus (pharmacologie)</term><term>Sirolimus (usage thérapeutique)</term><term>Sérine-thréonine kinases TOR (antagonistes et inhibiteurs)</term><term>Sérine-thréonine kinases TOR (métabolisme)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Cytokines</term><term>TOR Serine-Threonine Kinases</term></keywords><keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cell Proliferation</term><term>Gene Expression</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Expression des gènes</term><term>Prolifération cellulaire</term><term>Réplication virale</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cytokines</term><term>Sérine-thréonine kinases TOR</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Sirolimus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Repositioning</term><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term><term>Repositionnement des médicaments</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33031791</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2020</Year><Month>11</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7786</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><PubDate><Year>2020</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Chemico-biological interactions</Title><ISOAbbreviation>Chem Biol Interact</ISOAbbreviation></Journal><ArticleTitle>Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.</ArticleTitle><Pagination><MedlinePgn>109282</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0009-2797(20)31053-X</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cbi.2020.109282</ELocationID><Abstract><AbstractText>The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic. Currently, there is no vaccine to prevent infection nor any approved drug for the treatment. The development of a new drug is time-consuming and cannot be relied on as a solution in combatting the immediate global challenge. In such a situation, the drug repurposing becomes an attractive solution to identify the potential of COVID-19 treatment by existing drugs, which are approved for other indications. Here, we review the potential use of rapamycin, an mTOR (Mammalian Target of Rapamycin) inhibitor that can be repurposed at low dosages for the treatment of COVID-19. Rapamycin inhibits protein synthesis, delays aging, reduces obesity in animal models, and inhibits activities or expression of pro-inflammatory cytokines such as IL-2, IL-6 and, IL-10. Overall, the use of rapamycin can help to control viral particle synthesis, cytokine storms and contributes to fight the disease by its anti-aging and anti-obesity effects. Since, rapamycin targets the host factors and not viral machinery, it represents a potent candidate for the treatment of COVID-19 than antiviral drugs as its efficacy is less likely to be dampened with high mutation rate of viral RNA. Additionally, the inhibitory effect of rapamycin on cell proliferation may aid in reducing viral replication. Therefore, by drug repurposing, low dosages of rapamycin can be tested for the potential treatment of COVID-19/SARS-CoV-2 infection.</AbstractText><CopyrightInformation>Copyright © 2020 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Husain</LastName><ForeName>Amjad</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Science and Society, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India; Innovation and Incubation Centre for Entrepreneurship, Indian Institute of Science Education and Research (IISER), Bhopal, MP, India. Electronic address: amjad@iiserb.ac.in.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrareddy</LastName><ForeName>Siddappa N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Department of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Genetics, Cell Biology, and Anatomy, University of Nebraska Medical Centre, Omaha, NE, USA; Department of Biochemistry and Molecular Biology, University of Nebraska Medical Centre, Omaha, NE, USA. Electronic address: sid.byrareddy@unmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Chem Biol Interact</MedlineTA><NlmUniqueID>0227276</NlmUniqueID><ISSNLinking>0009-2797</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.1</RegistryNumber><NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>W36ZG6FT64</RegistryNumber><NameOfSubstance UI="D020123">Sirolimus</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020123" MajorTopicYN="N">Sirolimus</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Rapamycin</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">mTOR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>10</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>10</Month><Day>8</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33031791</ArticleId><ArticleId IdType="pii">S0009-2797(20)31053-X</ArticleId><ArticleId IdType="doi">10.1016/j.cbi.2020.109282</ArticleId><ArticleId IdType="pmc">PMC7536130</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Inde</li><li>États-Unis</li></country><region><li>Nebraska</li></region></list><tree><country name="Inde"><noRegion><name sortKey="Husain, Amjad" sort="Husain, Amjad" uniqKey="Husain A" first="Amjad" last="Husain">Amjad Husain</name></noRegion></country><country name="États-Unis"><region name="Nebraska"><name sortKey="Byrareddy, Siddappa N" sort="Byrareddy, Siddappa N" uniqKey="Byrareddy S" first="Siddappa N" last="Byrareddy">Siddappa N. Byrareddy</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000062 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000062 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Bois
|area= RapamycinFungusV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:33031791
|texte= Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:33031791" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a RapamycinFungusV1
| This area was generated with Dilib version V0.6.38. |  |